
Feb 10 (Reuters) - KAILERA THERAPEUTICS:
KAILERA THERAPEUTICS: CO, HENGRUI PHARMA REPORT POSITIVE TOPLINE DATA FROM PHASE 2 OBESITY TRIAL OF ORAL RIBUPATIDE
KAILERA THERAPEUTICS: MEAN WEIGHT LOSS OF UP TO 12.1% WITH NO OBSERVED PLATEAU AT 26 WEEKS IN PHASE 2 TRIAL IN CHINA WITH ORAL RIBUPATIDE
KAILERA THERAPEUTICS: HENGRUI TO TEST ORAL RIBUPATIDE IN PHASE 3 TRIAL IN CHINA; CO PLANS TO INITIATE GLOBAL PHASE 2 CLINICAL TRIAL IN 2026